Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
Hillstream BioPharma, Inc. Frequently Asked Questions
What is the ticker symbol for Hillstream BioPharma, Inc.? What does HILS stand for in stocks?
HILS is the stock ticker symbol of Hillstream BioPharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Hillstream BioPharma, Inc. (HILS)?
As of Thu Oct 31 2024, market cap of Hillstream BioPharma, Inc. is 2.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of HILS stock?
You can check HILS's fair value in chart for subscribers.
Is Hillstream BioPharma, Inc. a good stock to buy?
The fair value guage provides a quick view whether HILS is over valued or under valued. Whether Hillstream BioPharma, Inc. is cheap or expensive depends on the assumptions which impact Hillstream BioPharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HILS.
What is Hillstream BioPharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?
As of Thu Oct 31 2024, HILS's PE ratio (Price to Earnings) is -261.3 and Price to Sales (PS) ratio is 10.13 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HILS PE ratio will change depending on the future growth rate expectations of investors.